Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Sonoma Pharmaceuticals Inc SNOA

Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care... see more

Recent & Breaking News (NDAQ:SNOA)

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2019 Financial Results

GlobeNewswire July 8, 2019

Sonoma Pharmaceuticals Announces 1-for-9 Reverse Split of Outstanding Common Stock

GlobeNewswire June 19, 2019

Sonoma Pharmaceuticals Sells Animal Health Rights in Asia and Europe for $2.7 million

GlobeNewswire May 21, 2019

Sonoma Pharmaceuticals Announces Substantial Cost-Cutting Measures

GlobeNewswire March 12, 2019

Sonoma Pharmaceuticals Announces Management Changes

GlobeNewswire December 14, 2018

Factors of Influence in 2018, Key Indicators and Opportunity within Sphere 3D, Solar Senior Capital, The Intergroup, Constellation Pharmaceuticals, Sonoma Pharmaceuticals, and OFS Capital — New Research Emphasizes Economic Growth

GlobeNewswire November 21, 2018

Sonoma Pharmaceuticals Announces Pricing of Public Offering of Units

GlobeNewswire November 17, 2018

Sonoma Pharmaceuticals Reports Record Revenue in Second Quarter FY 2019

GlobeNewswire November 8, 2018

Sonoma Pharmaceuticals Announces Second Quarter FY 2019 Financial Results and Conference Call

GlobeNewswire November 1, 2018

Sonoma Pharmaceuticals Announces Newly Published Results from Study of Hypochlorous Acid in Management of Hypertrophic and Keloid Scars

GlobeNewswire October 25, 2018

Sonoma Pharmaceuticals Launches New Ceramax™ Skin Barrier Lotion with Skin-Enriching Lipogrid Technology™

GlobeNewswire October 17, 2018

Sonoma Pharmaceuticals Announces Licensing of Antimicrobial Hypochlorous Acid Solution for Management of Blepharitis in the Spanish/Portuguese Markets to Brill Pharma, S.L.

GlobeNewswire September 26, 2018

Sonoma Pharmaceuticals Appoints Phillipe Weigerstorfer to Board of Directors

GlobeNewswire September 19, 2018

Sonoma Pharmaceuticals Announces Results from Study of Sonoma’s Performance-Stabilized HOCl™ (Hypochlorous Acid) in Management of Acne Vulgaris

GlobeNewswire August 28, 2018

Sonoma Pharmaceuticals Reports First Quarter FY 2019 Financial Results

GlobeNewswire August 8, 2018

Sonoma Pharmaceuticals Announces First Quarter FY 2019 Financial Results and Conference Call

GlobeNewswire July 25, 2018

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2018 Financial Results

GlobeNewswire June 13, 2018

U.SK, dermatology arm of Brazilian NC Group, and Sonoma Pharmaceuticals Enter into License Agreement for Exclusive Rights to Sonoma’s Dermatology Products in Brazil

GlobeNewswire June 5, 2018

Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2018 Financial Results and Conference Call

GlobeNewswire May 31, 2018

Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer

GlobeNewswire May 8, 2018